🚀 Breaking News in Cardio-Oncology! 🫀🎗️

A new randomized trial in European Journal of Heart Failure shows that low-dose sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor) given before adjuvant therapy in early breast cancer patients completely prevented cancer therapy-related cardiac dysfunction (CTRCD) over 12 months — 0% vs 26.3% in standard care (p=0.006, NNT=3.8).

💡 Why it matters: CTRCD remains a major risk with anthracyclines and HER2-targeted therapy. Early ARNI initiation, guided by global longitudinal strain (GLS) monitoring, may offer a powerful primary prevention strategy.

📈 Takeaway: This could reshape cardio-oncology practice, but larger Phase III trials are needed to confirm long-term benefits.

#CardioOncology #HeartFailurePrevention #ARNI #BreastCancer #EJHF #CTRCD #GLS #LVEF #PrecisionMedicine #ClinicalTrials